A DNA methylation-based liquid biopsy for triple-negative breast cancer

Código QR

A DNA methylation-based liquid biopsy for triple-negative breast cancer

Abstract Here, we present a next-generation sequencing (NGS) methylation-based blood test called methylation DETEction of Circulating Tumour DNA (mDETECT) designed for the optimal detection and monitoring of metastatic triple-negative breast cancer (TNBC). Based on a highly multiplexed targeted sequ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katrina Cristall, Francois-Clement Bidard, Jean-Yves Pierga, Michael J. Rauh, Tatiana Popova, Clara Sebbag, Olivier Lantz, Marc-Henri Stern, Christopher R. Mueller
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ef969627e67f4e189931a3676d9f15a4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Amanda Bortolini Silveira, et al.
Publicado: (2021)

Liquid Biopsy and Primary Brain Tumors
por: Robert H. Eibl, et al.
Publicado: (2021)

Liquid biopsy. A challenge for clinical laboratories
por: Jiménez Wladimiro
Publicado: (2020)

Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer
por: Marta Łukasiewicz, et al.
Publicado: (2021)

Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR
por: Daphne Li, et al.
Publicado: (2021)

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations
por: Hoai-Nghia Nguyen, et al.
Publicado: (2021)

Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients
por: Brendan F. Miller, et al.
Publicado: (2021)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner J, et al.
Publicado: (2015)

Research Progress on CircRNA in Liquid Biopsy of Gastric Cancer
por: ZHU Hao, et al.
Publicado: (2021)

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Natasha Honoré, et al.
Publicado: (2021)

Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma
por: Kate I. Glennon, et al.
Publicado: (2021)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Vanessa Y. C. Sung, et al.
Publicado: (2021)

A triple negative breast cancer: what it is not!
por: Katakkar SB
Publicado: (2012)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
por: Wen-Hung Kuo, et al.
Publicado: (2012)

Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors
por: Kit Man Chan, et al.
Publicado: (2021)

Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics
por: Hoyoon Lee, et al.
Publicado: (2020)

Single-copy detection of somatic variants from solid and liquid biopsy
por: Ana-Luisa Silva, et al.
Publicado: (2021)

Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer
por: Yunee Kim, et al.
Publicado: (2016)

Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
por: Marinus Huber, et al.
Publicado: (2021)

Liquid Biopsy in Prostate Cancer Diagnosis and Prognosis: A Narrative Review
por: Seyed Saeed Tamehri Zadeh, et al.
Publicado: (2020)

BRCA2 mutations and triple-negative breast cancer.
por: Peter Meyer, et al.
Publicado: (2012)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
por: Steffen Grann Jensen, et al.
Publicado: (2021)

Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
por: Argyris C. Hadjimichael, et al.
Publicado: (2021)

Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering
por: Francesco Dell’Olio
Publicado: (2021)

Diagnostic potential of hypoxia-induced genes in liquid biopsies of breast cancer patients
por: Carlos Henrique F. Peiró, et al.
Publicado: (2021)

Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
por: Linghui Liang, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman ML, et al.
Publicado: (2015)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
por: Justin D. Finkle, et al.
Publicado: (2021)

Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy
por: Elyssa Y. Wong, et al.
Publicado: (2021)

Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools
por: Jessica Garcia, et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Anna E. M. Bastiaansen, et al.
Publicado: (2020)

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: L. E. Anselmino, et al.
Publicado: (2021)